Ver Donck K
Department of Biochemistry, Janssen Research Foundation, Beerse, Belgium.
Pharm World Sci. 1994 Apr 15;16(2):69-76. doi: 10.1007/BF01880658.
Adenosine has recently received much attention for the protection it provides against the deleterious effects of ischaemia reperfusion. Whenever the demand for oxygen exceeds its supply, adenosine triphosphate in myocytes is rapidly dephosphorylated to adenosine. Adenosine may then protect the myocardium against ischaemia-reperfusion damage. However, the accumulation of adenosine is limited by its rapid uptake and catabolism in the endothelium and in red blood cells. The strict compartmentalization of the enzyme pathways involved in the metabolism of adenosine, e.g. adenosine production by myocytes, its pharmacological action in the interstitium, its catabolism in the endothelium and in red blood cells, and its carrier-mediated transport across membranes, provides a unique target for pharmacological interventions. Blockade of adenosine uptake may indeed result in prolonged adenosine accumulation specifically in those regions of the heart where it is produced. In recent years considerable evidence has been gathered on the adenosine-mediated cardioprotective actions of nucleoside transport inhibitors.
腺苷最近因其对缺血再灌注有害影响的保护作用而备受关注。每当氧气需求超过供应时,心肌细胞中的三磷酸腺苷会迅速脱磷酸化为腺苷。腺苷随后可能保护心肌免受缺血再灌注损伤。然而,腺苷的积累受到其在内皮细胞和红细胞中快速摄取和分解代谢的限制。参与腺苷代谢的酶途径严格的区室化,例如心肌细胞产生腺苷、其在间质中的药理作用、其在内皮细胞和红细胞中的分解代谢以及其通过载体介导的跨膜转运,为药理干预提供了独特的靶点。阻断腺苷摄取确实可能导致腺苷在心脏产生部位的积累时间延长。近年来,关于核苷转运抑制剂的腺苷介导的心脏保护作用已经收集了大量证据。